Private equity has always rewarded patient capital. What it couldn’t always offer was a credible path to liquidity before a fund wound down. That’s changed with GP-led secondaries, continuation vehicles, and structured liquidity solutions which have matured from tactical workarounds into a strategic layer of the alternatives market.